KRTL Holding Group has acquired Neurogen Brain Balancing, LLC, a neurotechnology company known for its advanced brain-balancing therapies and personalized cognitive optimization systems. KRTL focuses on biotech innovation, regulatory infrastructure and strategic investment, and this acquisition expands its presence in the mental wellness space and strengthens its position in neuroscience, biotechnology and global healthcare.
With this acquisition, Neurogen becomes a wholly owned subsidiary of KRTL Holding Group, allowing KRTL to integrate Neurogen’s neurotechnology into its ecosystem and enable development of scalable mental health solutions.
According to a news release, KRTL acquired 100 percent of Neurogen’s equity through a stock-based transaction, which includes a collaborative profit-sharing agreement. As part of the deal, KRTL will support Neurogen’s expansion into new markets and provide FDA-regulated services to help accelerate growth and align regulatory strategies between both companies.
Neurogen’s neurotechnology uses neuromodulation protocols to enhance cognitive performance, reduce stress and support post-trauma recovery. The company aims to improve access to alternative therapies through a platform that offers non-invasive, non-opioid treatment options and addresses gaps in mental healthcare.
